Ixekizumab impact on itch severity compared to etanercept and placebo: Results from UNCOVER-2, a phase 3 trial in patients with moderate-to-severe plaque psoriasis

被引：0
|
作者：
Kimball, Alexa Boer [1 ,2 ]
Nikai, Enkeleida [3 ]
Zhu, Baojin [3 ]
Carlier, Hilde [3 ]
Yosipovitch, Gil [4 ]
机构：
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
[2] Harvard Univ, Sch Med, Boston, MA USA
[3] Eli Lilly & Co, Indianapolis, IN 46285 USA
[4] Temple Univ, Philadelphia, PA 19122 USA
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2015年 / 135卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P066
引用
收藏
页码：S19 / S19
页数：1
相关论文
共 50 条
  • [1] Ixekizumab impact on health-related quality of life compared to etanercept and placebo: Results from UNCOVER-2, a phase 3 trial in patients with moderate-to-severe plaque psoriasis
    Reich, Kristian
    Toth, Darryl
    Nikai, Enkeleida
    Zhu, Baojin
    Carlier, Hilde
    Feldman, Steven
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S35 - S35
  • [2] A Phase 3 Trial Comparing Ixekizumab with Placebo and Etanercept for Moderate-to-Severe Plaque Psoriasis: Results from the 12 Week Induction Period of UNCOVER-2
    Griffiths, C. E. M.
    Leutz, A.
    Reich, K.
    Lebwohl, M.
    van de Kerkhof, P.
    Paul, C.
    Menter, A.
    Cameron, G. S.
    Erickson, J.
    Zhang, L.
    Secrest, R.
    Ball, S.
    Braun, D.
    Osuntokun, O. O.
    Heffernan, M.
    Nickoloff, B. J.
    Papp, K.
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2016, 14 : 3 - 3
  • [3] A phase 3 trial comparing ixekizumab with placebo and etanercept for moderate-to-severe plaque psoriasis: Results from the 12 week induction period of UNCOVER-2
    Griffiths, Christopher E.
    Reich, Kristian
    Lebwohl, Mark
    Van de Kerkhof, Peter
    Paul, Carle
    Menter, Alan
    Carlier, Hilde
    Cameron, Gregory
    Erickson, Janelle
    Zhang, Lu
    Secrest, Roberta
    Ball, Susan
    Braun, Daniel
    Osuntokun, Olawale
    Heffernan, Michael
    Nickoloff, Brian
    Papp, Kim
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S17 - S17
  • [4] Impact of ixekizumab on skin pain in patients with moderate to severe psoriasis compared to placebo and etanercept in UNCOVER-2
    Gottlieb, Alice
    Luger, Thomas
    Puig Sanz, Luis
    Enkeleida, Nikai
    Zhu, Baojin
    Edson-Heredia, Emily
    Carlier, Hilde
    Lin, Chen-Yen
    Bleakman, Alison Potts
    Goldblum, Orin
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB57 - AB57
  • [5] Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
    Griffiths, Christopher E. M.
    Reich, Kristian
    Lebwohl, Mark
    van de Kerkhof, Peter
    Paul, Carle
    Menter, Alan
    Cameron, Gregory S.
    Erickson, Janelle
    Zhang, Lu
    Secrest, Roberta J.
    Ball, Susan
    Braun, Daniel K.
    Osuntokun, Olawale O.
    Heffernan, Michael P.
    Nickoloff, Brian J.
    Papp, Kim
    [J]. LANCET, 2015, 386 (9993): : 541 - 551
  • [6] Improvements in fingernail lesions in patients with moderate-to-severe psoriasis treated with ixekizumab versus placebo and etanercept: Results from UNCOVER-2
    van de Kerkhof, Peter
    Guenther, Lyn
    Gottlieb, Alice
    Sebastian, Michael
    Wu, Jashin J.
    Foley, Peter
    Morita, Akimichi
    Goldblum, Orin
    Kerr, Lisa
    Rich, Phoebe
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB255 - AB255
  • [7] Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3)
    Menter, A.
    Warren, R. B.
    Langley, R. G.
    Merola, J. F.
    Kerr, L. N.
    Dennehy, E. B.
    Shrom, D.
    Amato, D.
    Okubo, Y.
    Reich, K.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (10) : 1686 - 1692
  • [8] A phase 3 trial comparing ixekizumab with placebo and etanercept for moderate-to-severe plaque psoriasis: Results from the 12 week induction period of UNCOVER 3
    Griffiths, Christopher E.
    Reich, Kristian
    Lebwohl, Mark
    Van de Kerkhof, Peter
    Paul, Carle
    Menter, Alan
    Carlier, Hilde
    Cameron, Gregory
    Erickson, Janelle
    Zhang, Lu
    Secrest, Roberta
    Ball, Susan
    Braun, Daniel
    Osuntokun, Olawale
    Heffernan, Michael
    Nickoloff, Brian
    Papp, Kim
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S17 - S17
  • [9] Efficacy of ixekizumab in patients with and without previous experience with biologic therapies compared to etanercept and placebo: results from UNCOVER-2, a phase 3 trial in patients with plaque psoriasis
    Lacour, Jean-Philippe
    Dutronc, Yves
    Zhang, Lu
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S6 - S6
  • [10] Efficacy of Ixekizumab in Patients with and without Previous Experience with Biologic Therapies Compared to Etanercept and Placebo: Results from UNCOVER-2, a Phase 3 Trial in Patients with Plaque Psoriasis
    Lacour, J. -P.
    Leutz, A.
    Dutronc, Y.
    Zhang, L.
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2016, 14 : 4 - 4
12345